Circulating cell-free DNA content as blood based biomarker in endometrial cancer

Oncotarget

Volumn 8, Issue 70, 2017, Pages 115230-115243

  Cicchillitti, Lucia ^a   Corrado, Giacomo ^b   de Angeli, Martina ^c   Mancini, Emanuela ^a   Baiocco, Ermelinda ^a   Patrizi, Lodovico ^c   Zampa, Ashanti ^a   Merola, Roberta ^a   Martayan, Aline ^a   Conti, Laura ^a   Piaggio, Giulia ^a   Vizza, Enrico ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Bio markers; Circulating cell free DNA; Circulating cell free mitochondrial DNA; Endometrial cancer; Liquid biopsy

Indexed keywords

BIOLOGICAL MARKER; DNA; MITOCHONDRIAL DNA;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA CONTENT; DNA DETERMINATION; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; NEUTROPHIL LYMPHOCYTE RATIO;

EID: 85039714795     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.23247     Document Type: Article

References (47)

1. Mandel P, Metais P. Les acides nucleiques du plasma sanguine chez I'homme. C R Seances Soc Biol Fil. 1948; 142:241-43
2. Leon SA, Green A, Yaros MJ, Shapiro B. Radioimmunoassay for nanogram quantities of DNA. J Immunol Methods. 1975; 9:157-64
3. Stroun M, Lyautey J, Lederrey C, Mulcahy HE, Anker P. Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA: evidence for a preferential release from viable cells? Ann N Y Acad Sci. 2001; 94:258-64
4. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001; 61:1659-65
5. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11:426-437
6. Silvestris N, Ciliberto G, De Paoli P, Apolone G, Lavitrano ML, Pierotti MA, Stanta G; On the behalf of the 'dynamic medicine OECI group'. Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research. J Exp Clin Cancer Res. 2017; 36:128
7. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer. 2009; 8:105. https://doi. org/10.1186/1476-4598-8-105
8. Zachariah RR, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol. 2008; 112:843-50. https://doi. org/10.1097/AOG.0b013e3181867bc0
9. Li L, Hann HW, Wan S, Hann RS, Wang C, Lai Y, Ye X, Evans A, Myers RE, Ye Z, Li B, Xing J, Yang H. Cellfree circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection. Sci Rep. 2016; 6:23992. https://doi.org/10.1038/ srep23992
10. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011; 11:325-37. https://doi.org/10.1038/ nrc3038
11. Boyapati RK, Tamborska A, Dorward DA, Ho GT. Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases. F1000Res. 2017; 6:169. https://doi.org/10.12688/ f1000research.10397.1
12. Larsen NB, Rasmussen M, Rasmussen LJ. Nuclear and mitochondrial DNA repair: similar pathways? Mitochondrion. 2005; 5:89-108
13. Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015; 6:111
14. Yu M. Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers. Life Sci. 2011; 89:65-71
15. Coskun P, Wyrembak J, Schriner SE, Chen HW, Marciniack C, Laferla F, Wallace DC. A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta. 2012; 1820:553-64
16. Sun Y, Zhang L, Ho SS, Wu X, Gu J. Lower mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of endometrial cancer. Mol Carcinog. 2016; 55:1111-7. https://doi.org/10.1002/mc.22373
17. Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklinska W, Chyczewski L, Kulikowski M. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer. 2010; 127:612-21. https:// doi.org/10.1002/ijc.25077
18. Tanaka H, Tsuda H, Nishimura S, Nomura H, Kataoka F, Chiyoda T, Tanaka K, Iguchi Y, Susumu N, Aoki D. Role of circulating free alu DNA in endometrial cancer. Int J Gynecol Cancer. 2012; 22:82-6. https://doi.org/10.1097/ IGC.0b013e3182328c94
19. Furda AM, Bess AS, Meyer JN, Van Houten B. Analysis of DNA damage and repair in nuclear and mitochondrial DNA of animal cells using quantitative PCR. Methods Mol Biol. 2012; 920:111-32. https://doi. org/10.1007/978-1-61779-998-3_9
20. Rooney JP, Ryde IT, Sanders LH, Howlett EH, Colton MD, Germ KE, Mayer GD, Greenamyre JT, Meyer JN. PCR based determination of mitochondrial DNA copy number in multiple species. Methods Mol Biol. 2015; 1241:23-38. https://doi.org/10.1007/978-1-4939-1875-1_3
21. Goldshtein H, Hausmann MJ, Douvdevani A. A rapid direct fluorescent assay for cell-free DNA quantification in biological fluids. Ann Clin Biochem. 2009; 46:488-94. https://doi.org/10.1258/acb.2009.009002
22. Letendre JA, Goggs R. Measurement of plasma cell-free DNA concentrations in dogs with sepsis, trauma, and neoplasia. J Vet Emerg Crit Care (San Antonio). 2017; 27:307-14. https://doi.org/10.1111/vec.12592
23. Lazarev I, Leibovitch L, Czeiger D, Sion-Vardi N, Geffen DB, Douvdevani A, Ariad S. Cell-free DNA blood levels in colorectal cancer patients do not correlate with mismatch repair-proficiency. In Vivo. 2014; 28:349-54
24. Agassi R, Czeiger D, Shaked G, Avriel A, Sheynin J, Lavrenkov K, Ariad S, Douvdevani A. Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast cancer. Am J Clin Pathol. 2015; 143:18-24
25. Czeiger D, Shaked G, Sebbag G, Vakhrushev A, Flomboym A, Lior Y, Belochitski O, Ariad S, Douvdevani A. Elevated cell-free DNA measured by a simple assay is associated with increased rate of colorectal cancer relapse. Am J Clin Pathol. 2016; 145:852-7. https://doi.org/10.1093/ajcp/ aqw068
26. Czeiger D, Shaked G, Eini H, Vered I, Belochitski O, Avriel A, Ariad S, Douvdevani A. Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer. Am J Clin Pathol. 2011; 135:264-70. https://doi.org/10.1309/ AJCP4RK2IHVKTTZV
27. Aune D, Sen A, Vatten LJ. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies. Sci Rep. 2017; 7:44808. https://doi.org/10.1038/srep44808
28. Peters DL, Pretorius PJ. Origin, translocation and destination of extracellular occurring DNA-a new paradigm in genetic behaviour. Clin Chim Acta. 2011; 412:806-11. https://doi.org/10.1016/j.cca.2011.01.026
29. Frank MO. Circulating cell-free DNA differentiates severity of inflammation. Biol Res Nurs. 2016; 18:477-88. https:// doi.org/10.1177/1099800416642571
30. Platz CE, Benda JA. Female genital tract cancer. Cancer. 1995; 75:270-94
31. Yoshida H, Imai Y, Fujiwara K. Combination chemotherapy with docetaxel and carboplatin for elderly patients with endometrial cancer. Mol Clin Oncol. 2016; 4:783-8
32. Jylhävä J, Kotipelto T, Raitala A, Jylhä M, Hervonen A, Hurme M. Aging is associated with quantitative and qualitative changes in circulating cell-free DNA: the Vitality 90+ study. Mech Ageing Dev. 2011; 132:20-6. https://doi. org/10.1016/j.mad.2010.11.001
33. Knez J, Winckelmans E, Plusquin M, Thijs L, Cauwenberghs N, Gu Y, Staessen JA, Nawrot TS, Kuznetsova T. Correlates of peripheral blood mitochondrial DNA content in a general population. Am J Epidemiol. 2016; 183:138-46. https://doi.org/10.1093/aje/kwv175
34. Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013; 108:901-7. https://doi. org/10.1038/bjc.2013.28
35. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, Park KJ, Roh MS, Kim SG, Kim HJ, Lee JH. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer Biomarkers. 2012; 17:216-22. https://doi. org/10.3109/1354750X.2012.656705
36. He G, Zhang H, Zhou J, Wang B, Chen Y, Kong Y, Xie X, Wang X, Fei R, Wei L, Chen H, Zeng H. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015; 34:141
37. Ural üM, Sehitoglu I, Tekin YB, Sahin FK. Neutrophil-tolymphocyte and platelet-to-lymphocyte ratios in patients with endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res. 2015; 41:445-8. https://doi. org/10.1111/jog.12536
38. Cummings M, Merone L, Keeble C, Burland L, Grzelinski M, Sutton K, Begum N, Thacoor A, Green B, Sarveswaran J, Hutson R, Orsi NM. Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. Br J Cancer. 2015; 113:311-20. https://doi. org/10.1038/bjc.2015.200
39. Ethier JL, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecol Oncol. 2017; 145:584-94. https://doi.org/10.1016/j.ygyno.2017.02.026
40. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016; 16:431-46. https://doi.org/10.1038/nrc.2016.52
41. Demers M, Wagner DD. Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2013; 2:e22946
42. Cedervall J, Zhang Y, Olsson AK. Tumor-induced NETosis as a risk factor for metastasis and organ failure. Cancer Res. 2016; 76:4311-5. https://doi.org/10.1158/0008-5472. CAN-15-3051
43. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010; 107:15880-5. https://doi.org/10.1073/pnas.1005743107
44. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010; 16:887-96. https://doi.org/10.1038/nm.2184
45. Deng L, Gao Y, Li X, Cai M, Wang H, Zhuang H, Tan M, Liu S, Hao Y, Lin B. Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma. J Exp Clin Cancer Res. 2015; 34:96
46. Cicchillitti L, Corrado G, Carosi M, Dabrowska ME, Loria R, Falcioni R, Cutillo G, Piaggio G, Vizza E. Prognostic role of NF-YA splicing isoforms and Lamin A status in low grade endometrial cancer. Oncotarget. 2017; 8:7935-45. https://doi.org/10.18632/oncotarget.13854
47. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497:67-73. https:// doi.org/10.1038/nature12113. Erratum in: Nature. 2013; 500:242